Pharmaceutical Executive
Companies Face Costly System Overhauls With New FDA Regulations
Mark E. Kolb
Advertisement
Mark E. Kolb is CEO of Taratec Development, a consulting firm that provides e-technology and regulatory solutions for the life sciences industry.
Articles by Mark E. Kolb
Advertisement
Latest Updated Articles
- The Next Y2K
May 1st 2001
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5